November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD

Board of Directors

Board of Directors

Arnold Snider: Chairman

Joseph Loscalzo, M.D., PhD

Harvard Medical School

Howard Furst, M.D.

Deerfield Management

Michael Treisman

Tiger Management

Charles Scoggin, M.D.

CEO, N30 Pharmaceuticals

Evan Loh, M.D., FACC, FAHA

John Moore

Array BioPharma

January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement